Spero Therapeutics (SPRO) EBITDA (2016 - 2026)
Spero Therapeutics posted quarterly EBITDA of -$7.5 million for Q1 2026, up 48.83% year-on-year from -$5.1 million in Q1 2025, and down 124.0% on a QoQ basis from $31.4 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of EBITDA data on file, last reported at -$7.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 48.83% year-over-year to -$7.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (up 117.37% YoY), and the FY2025 full-year result was $6.3 million, up 108.61% from the prior year.
- EBITDA for Q1 2026 stood at -$7.5 million, down from $31.4 million in the prior quarter.
- Across five years, EBITDA topped out at $51.2 million in Q4 2023 and bottomed at -$32.8 million in Q1 2022.
- The 5-year median for EBITDA is -$11.9 million (2023), against an average of -$6.0 million.
- The widest annual swing landed in 2024, when EBITDA slumped 480.12%; it then jumped 223.68% in 2025.
- A 5-year view of EBITDA shows it stood at $26.8 million in 2022, then surged by 91.22% to $51.2 million in 2023, then tumbled by 149.6% to -$25.4 million in 2024, then surged by 223.68% to $31.4 million in 2025, then sank by 124.0% to -$7.5 million in 2026.
- The last three EBITDA figures came in at -$7.5 million (Q1 2026), $31.4 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -7.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.54 Mn |
| Dec 31, 2025 | 31.41 Mn |
| Sep 30, 2025 | -7.92 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Mar 31, 2025 | -14.73 Mn |
| Dec 31, 2024 | -25.39 Mn |
| Sep 30, 2024 | -18.59 Mn |
| Jun 30, 2024 | -19.06 Mn |
| Mar 31, 2024 | -13.98 Mn |
| Dec 31, 2023 | 51.19 Mn |
| Sep 30, 2023 | -3.21 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | -13.27 Mn |
| Dec 31, 2022 | 26.77 Mn |
| Sep 30, 2022 | -11.68 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -32.83 Mn |
| Dec 31, 2021 | -29.24 Mn |
| Sep 30, 2021 | 22.52 Mn |
| Jun 30, 2021 | -18.57 Mn |
| Mar 31, 2021 | -19.42 Mn |
| Dec 31, 2020 | -18.59 Mn |
| Sep 30, 2020 | -18.95 Mn |
| Jun 30, 2020 | -17.47 Mn |
| Mar 31, 2020 | -23.29 Mn |
| Dec 31, 2019 | -24.99 Mn |
| Sep 30, 2019 | -17.71 Mn |
| Jun 30, 2019 | -13.15 Mn |
| Mar 31, 2019 | -5.04 Mn |
| Dec 31, 2018 | -10.60 Mn |
| Sep 30, 2018 | -10.47 Mn |
| Jun 30, 2018 | -9.94 Mn |
| Mar 31, 2018 | -10.67 Mn |
| Dec 31, 2017 | -13.87 Mn |
| Sep 30, 2017 | -9.84 Mn |
| Jun 30, 2017 | -9.76 Mn |
| Mar 31, 2017 | -6.41 Mn |
| Dec 31, 2016 | -8.81 Mn |
| Sep 30, 2016 | -7.91 Mn |